unintentional injuries (82%) were similar pre and post equipment removal.
A FAMILY FOCUSED CLINICAL PATHWAY DECREASES LENGTH OF STAY IN A LEVEL 2 NEWBORN CENTRE
Clinical pathways (CP) are multidisciplinary care guidelines intended to improve efficiency of care. We have shown that neither health care provider focused nor family focused CP's, used in the step-down nursery of a tertiary NICU, resulted in earlier discharge of preterm infants. The opening of a new Level 2 newborn unit at an academic health centre provided an opportunity to evaluate the effectiveness of CP's in an alternate setting. Objective: To determine whether implementation of family focused CP's in a Level 2 newborn centre decreases length of stay. Methods: Previously developed family focused CP's that described postmenstrual age (PMA) dependent care activities undertaken by parents in preparation for their infant's discharge home were initiated in September 2002 for all infants admitted to the Level 2 unit. Data were collected for infants 29 -36 weeks gestation at birth. Two cohorts were compared: June -August, 2002 (pre-CP, n = 33) and Sept -Nov, 2002 (post-CP, n= 37) . Inborn infants and infants transferred from regional tertiary NICU's were included. A satisfaction questionnaire was administered to staff and families who had used the CP's. Results: Birthweight (1933±503 vs 2153±478 gms) , PMA at birth (33.2±1.9 vs 33.9±1.8 wks) and PMA and weight on admission to Level 2 (34.3±1.8 vs 34.5±1.1 wks; 1970±483 vs 2161±446 gms) were similar in the 2 cohorts (pre-CP vs post-CP, mean ± sd, p > 0.05). There were no differences in Apgar score, need for ventilatory support or oxygen and incidence of breastfeeding. More babies were transferred from tertiary NICU's in the pre-CP group (76% vs 46%, p=0.01). Length of stay in Level 2 (17.4±9.2 vs 12.8±7.8 days, p = 0.03) and PMA at discharge home (36.8±1.2 vs 36.3±0.9 wks, p=0.05) were significantly greater in the pre-CP group. Satisfaction scores for both staff and families were high. Conclusion: Implementation of family focused CP's in a Level 2 centre decreased length of stay for preterm infants and resulted in earlier discharge home. Use of CP's met with a high degree of staff and family satisfaction.
MATERNAL HYPOTHYROIDISM AND CONGENITAL HEART DISEASE: IS THERE A RELATIONSHIP?
S Vohra, L Hornberger, D Stephens, R Hamilton The Hospital for Sick Children, Toronto, Ontario Background: There is some early evidence that maternal hypothyroidism and thyroid replacement therapy may be linked to congenital heart disease in the newborn. MADRE, a population-based sample, did an analysis on their preliminary data set and found a significant association between cardiac septal defects and thyroid therapy (odds ratio 4.1, 95% CI=1.23-11.77, p=0.022) (Robert et al Int J Risk and Safety 1994) . Study question: Does maternal hypothyroidism and/or thyroid hormone replacement therapy during the first trimester of pregnancy affect the incidence of congenital heart disease? Methods: A case-control study set in the echocardiography lab within the cardiology department at The Hospital for Sick Children (Toronto). The endpoint (presence/absence of heart disease) was confirmed by the "gold" standard of echocardiography. Exposure data in this pilot study will be ascertained by maternal history as is standard in teratology research. Results: 700 cases (congenital heart disease present) and 309 controls (congenital heart disease absent) were obtained. The unadjusted odds of having maternal hypothyroidism in the cases vs. controls was not significant (OR 1.4, 95% CI= 0.86 to 2.27, p=0.15). When adjusted for other factors that could affect outcome, such as maternal diabetes, advanced maternal age, family history of congenital heart disease, and chromosomal disorders, the odds ratio was 2.04 (p=0.07). Conclusions: More rigorous prospective studies need to be done to examine the relationship between maternal thyroid function and congenital heart disease. Background: Alopecia areata is a cosmetically disfiguring, idiopathic disorder that can affect any hair bearing area of the body. There are few data on prognostic indicators and treatment of alopecia areata in children. Objective: To characterize the clinical profile, and determine response to treatment in children with alopecia areata. Methods: Information on children with alopecia areata who attended an urban tertiary pediatriac dermatology clinic during the period January 2001 -December 2001 inclusive, was collected. The medical charts were used to collect information on: age, sex, past medical history, family medical history, presenting pattern, treatment in clinic, and treatment side effects. Results: In total 79 patients presented with alopecia areata. The average age was 8 years (range 1-17years). Four cases (5%) were congenital and 41 (52%) occurred before the age of 6 years. Forty seven (60%) were female. Nail changes were noted in 12 (15%) and atopy in 12 (15%). Autoimmune disease was present in 4 patients (5%) and in the family history of 14 (17%). Initial treatment was as follows: 47 (60%) patients were commenced on high potency class 1 topical steroid clobetasol propionate, 15 (19%) were commenced on a class 2 topical steroid, 8 (10%) were commenced on a class 3 topical steroid, 8 (10%) did not receive any treatment and 1 patient was commenced on topical tacrolimus. Of patients treated with clobetasol propionate, response to treatment at 3 months was as follows: 18/22 (80%) patients with moderate alopecia areata; 2/3 (66%) patients with severe patchy alopecia areata; 6/10 (60%) patients with alopecia totalis. Skin atrophy was seen in 6 patients with continuous use of the clobetasol propionate, which resolved in all with intermittent therapy. Discussion: This is the first study of alopecia areata in children in North America. Our findings of female preponderance, lower age of onset, the frequency of congenital alopecia areata, and the low incidence of autoimmune disease in the children and their families, have not previously been reported. High potency clobetasol propionate was effective in the majority of children with alopecia areata, with no long term clinical adverse effects.
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ELEVATED CYTOKINES AND POOR NEURODEVELOPMENTAL OUTCOME IN NECROTIZING ENTEROCOLITIS
A Lodha, E Asztalos, A Moore Division of Neonatology, The Hospital for Sick Children, Toronto, Ontario; University of Toronto, Toronto, Ontario; Sunnybrook and Women's College Health Sciences Centre, Toronto, Ontario Background: There is increasing evidence that proinflammatory cytokines are important intermediates in the pathogenesis of cerebral palsy. Increased levels of tissue and circulating inflammatory cytokines have been reported in necrotizing enterocolitis (NEC). Increased levels of inflammatory and have also been correlated with disease severity and short-term outcome. NEC is also recognized as an independent risk factor 
